These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 9126882)

  • 1. D1 dopamine receptor activity of anti-parkinsonian drugs.
    Fici GJ; Wu H; VonVoigtlander PF; Sethy VH
    Life Sci; 1997; 60(18):1597-603. PubMed ID: 9126882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D2 and D1 dopaminergic activity of 7-OH-DPAT.
    Sethy VH; Ellerbrock BR; Fici GJ; Wu H
    Brain Res; 1996 Sep; 733(1):41-5. PubMed ID: 8891246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia.
    O'Neill MJ; Hicks CA; Ward MA; Cardwell GP; Reymann JM; Allain H; Bentué-Ferrer D
    Eur J Pharmacol; 1998 Jul; 352(1):37-46. PubMed ID: 9718265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
    Perachon S; Schwartz JC; Sokoloff P
    Eur J Pharmacol; 1999 Feb; 366(2-3):293-300. PubMed ID: 10082211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors.
    Andringa G; Drukarch B; Leysen JE; Cools AR; Stoof JC
    Eur J Pharmacol; 1999 Jan; 364(1):33-41. PubMed ID: 9920182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic control of angiotensin II-induced vasopressin secretion in vitro.
    Rossi NF
    Am J Physiol; 1998 Oct; 275(4):E687-93. PubMed ID: 9755089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
    Lindgren HS; Ohlin KE; Cenci MA
    Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.
    Piercey MF; Hoffmann WE; Smith MW; Hyslop DK
    Eur J Pharmacol; 1996 Sep; 312(1):35-44. PubMed ID: 8891576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parametric and pharmacological analyses of the enhanced grooming response elicited by the D1 dopamine receptor agonist SKF 38393 in the rat.
    Wachtel SR; Brooderson RJ; White FJ
    Psychopharmacology (Berl); 1992; 109(1-2):41-8. PubMed ID: 1365670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens; turning behaviour.
    Koshikawa N; Kitamura M; Kobayashi M; Cools AR
    Eur J Pharmacol; 1996 Jul; 308(3):235-41. PubMed ID: 8858293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor actions of 7-OH-DPAT in normal and reserpine-treated mice suggest involvement of both dopamine D2 and D3 receptors.
    Starr MS; Starr BS
    Eur J Pharmacol; 1995 Apr; 277(2-3):151-8. PubMed ID: 7493603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs.
    Cousins MS; Carriero DL; Salamone JD
    Eur J Pharmacol; 1997 Mar; 322(2-3):137-45. PubMed ID: 9098680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased striatal dopamine efflux after intrastriatal application of benzazepine-class D1 agonists is not mediated via dopamine receptors.
    Zackheim JA; Abercrombie ED
    Brain Res Bull; 2001 Apr; 54(6):603-7. PubMed ID: 11403986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SKF 83959 is an antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus accumbens: a key to its antiparkinsonian effect in animals?
    Cools AR; Lubbers L; van Oosten RV; Andringa G
    Neuropharmacology; 2002 Feb; 42(2):237-45. PubMed ID: 11804620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes.
    Ohta K; Kuno S; Mizuta I; Fujinami A; Matsui H; Ohta M
    Life Sci; 2003 Jun; 73(5):617-26. PubMed ID: 12770616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum.
    De Keyser J; De Backer JP; Wilczak N; Herroelen L
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1147-54. PubMed ID: 8787038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors.
    Seeman P
    Synapse; 2007 Dec; 61(12):1013-8. PubMed ID: 17853435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of D1 and D2 dopamine receptors increases the activity of the somatostatin receptor-effector system in the rat frontoparietal cortex.
    Izquierdo-Claros RM; del Boyano-Adánez M; Arilla-Ferreiro E
    J Neurosci Res; 2000 Oct; 62(1):91-8. PubMed ID: 11002291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the dopamine receptor expressed by rat glomerular mesangial cells in culture.
    Bryson SE; Drew GM; Hall AS; Ball SG; Balmforth AJ
    Eur J Pharmacol; 1992 Jan; 225(1):1-5. PubMed ID: 1347268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.